Table 1.
Background Variables
| Patient Characteristics | % of Patients | |
|---|---|---|
| Pretreatment fatigue score | ||
| Mean | 19.2 | |
| SD | 3.3 | |
| Range | 18-64 | |
| Pretreatment distress score | ||
| Mean | 26.9 | |
| SD | 3.7 | |
| Range | 0.100 | |
| Age, years | ||
| Mean | 44.5 | |
| SD | 1.2 | |
| Range | 29-76 | |
| Age group, years | ||
| < 50 | 28.6 | |
| > 50 | 71.4 | |
| Ethnicity | ||
| White | 83.9 | |
| Nonwhite | 16.1 | |
| Marital status, % of patients | ||
| Not married | 32.1 | |
| Married/living with partner | 67.9 | |
| Hours of sleep last night | ||
| Mean | 6.1 | |
| SD | 0.2 | |
| Range | 3-10 | |
| Chemotherapy regimen, % | ||
| CMF | 61.1 | |
| ACMF | 11.1 | |
| ATC | 27.8 | |
| Stage | ||
| I | 32.6 | |
| II | 67.4 |
NOTE. N varies due to missing data. For reference, a recently published study22 found that healthy adults whose levels of current fatigue were assessed using a VAS had a mean fatigue score of 19.7 (of a possible 100). In addition, using an identical VAS measure we have recently found mean distress levels of 38.2 in patients assessed in the clinic prior to breast surgery.23
Abbreviations: CMF, cyclophosphamide-methotrexate-fluorouracil; ACMF, adriamycin-cyclophosphamide-methotrexate-fluorouracil; ATC, adriamycin-paclitaxel-cyclophosphamide; SD, standard deviation.